IceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Growth in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 196,500 shares, a growth of 26.9% from the June 30th total of 154,900 shares. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 264,000 shares, the days-to-cover ratio is currently 0.7 days.

IceCure Medical Trading Down 4.7 %

Shares of ICCM opened at $0.76 on Friday. The stock’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $1.12. IceCure Medical has a twelve month low of $0.52 and a twelve month high of $1.57. The company has a current ratio of 3.39, a quick ratio of 2.88 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $34.79 million, a P/E ratio of -2.31 and a beta of 0.57.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, May 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). IceCure Medical had a negative return on equity of 101.66% and a negative net margin of 444.30%. The business had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.80 million. During the same quarter in the previous year, the business earned ($0.08) EPS. On average, equities research analysts forecast that IceCure Medical will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of IceCure Medical in a report on Tuesday, July 2nd.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.